

(19)



Europäisches Patentamt  
European Patent Office  
Office européen des brevets



(11)

**EP 0 714 663 A3**

(12)

**EUROPEAN PATENT APPLICATION**

(88) Date of publication A3:  
15.01.1997 Bulletin 1997/03

(43) Date of publication A2:  
05.06.1996 Bulletin 1996/23

(21) Application number: 95308407.6

(22) Date of filing: 25.11.1995

(51) Int Cl.<sup>6</sup>: **A61K 45/06, A61K 31/445**  
// (A61K31/445, 31:135),  
(A61K31/445, 31:145),  
(A61K31/445, 31:34),  
(A61K31/445, 31:40)

(84) Designated Contracting States:  
**AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT**  
**SE**

(30) Priority: 28.11.1994 US 345672

(71) Applicant: **ELI LILLY AND COMPANY**  
Indianapolis, Indiana 46285 (US)

(72) Inventors:  
• **Ogulza, Juan Ignacio**  
28700 San Sebastian de los Reyes Madrid (ES)

• **Wong, David Taiwai**  
Indianapolis, Indiana 46226 (US)

(74) Representative: **Tapping, Kenneth George et al**  
Lilly Industries Limited  
European Patent Operations  
Erl Wood Manor  
Windlesham Surrey GU20 6PH (GB)

(54) **Potentialiation of drug response by a serotonin 1A receptor antagonist**

(57) The power of citalopram, fluvoxamine and paroxetine to increase the availability of serotonin, nore-

pinephrine and dopamine, particularly serotonin, is augmented by administration in combination with a drug which is a serotonin 1A receptor antagonist.

**EP 0 714 663 A3**